MORE►
biotechnology
Video still from Lupagen's website. [Image: Lupagen}
Dallas Biotech Lupagen Partners With Global Transfusion Leader to Advance Bedside Cell and Gene Therapy
by Quincy Preston | Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
by Quincy Preston |
Sep 1, 2023
Tarleton State University received the go-ahead for a new biotechnology institute as part of Texas A&M-Fort Worth’s burgeoning downtown research campus.
Approved in mid-August by the Texas A&M University System Board of Regents, the biotech institute is situated in one of the nation’s fastest-growing life sciences hubs....
MORE►
by Lance Murray |
Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
by Lance Murray |
Jun 14, 2023
The alliance's first event will be held June 22 in a bid to champion a next-generation, industry-led workforce partnership for North Texas. The alliance seeks to bring together industry trade and manufacturing ecosystems, the organizations said—and it will be working with Dallas College and other partner institutions to help make it happen.
MORE►
Illustration: peterschreiber.media/iStock
Southlake Biotech Renibus Therapeutics Garners $33M in Bridge Financing
by Lance Murray | Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
Brandom Gengelbach [Photo: Courtesy Fort Worth Chamber]
New Fort Worth Chamber CEO Aims for Growth, Innovation, and Development
by Alex Edwards | Sep 22, 2020
CEO Brandom Gengelbach says he’s doing business differently in the fast-growing city “where the West begins.”
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-360x203.jpg)
by Quincy Preston |
Sep 22, 2020
Networking—always a highlight of the biotech event— is still a cornerstone thanks to a new virtual conference platform, its organizers said.
MORE►
by Alex Edwards |
Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
by Quincy Preston |
Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
[Image: iStockphoto]
Clinical-Stage Biotech Expands From Silicon Valley to the University of North Texas Health Science Center in Fort Worth
by Alex Edwards | Jul 13, 2020
CAGE Bio—currently a resident at Johnson & Johnson Innovation—uses a proprietary platform to develop therapeutic products for dermatology, inflammation, and immunology.
MORE►
by Lauren Hawkins |
May 4, 2020
Last month, Allied BioScience received capital from Lydia Partners to scale its operations and meet a surging demand.
MORE►
by Lance Murray |
Jun 28, 2018
From Viziv Technologies raising another $576,000 for energy technology and Stryve Foods raising $10 million, here's a look at recent funding and acquisitions involving companies and firms with North Texas ties.
MORE►
by Heather Noel |
Oct 4, 2016
The life science industry association has more than 70 North Texas companies and 20 individuals or job seekers within its membership.
MORE►
